SCHOLAR ROCK HOLDING CORPORATION Restructuring and Related Cost, Number of Positions Eliminated
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Restructuring and Related Cost, Number of Positions Eliminated of 39 position for the 3-month period ending 2022-06-30, per its 10-K filed 2024-03-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2024-03-19
- SCHOLAR ROCK HOLDING CORPORATION restructuring and related cost, number of positions eliminated for the quarter ending 2022-06-30 was 39.00 position.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated | Restructuring and Related Cost, Number of Positions Eliminated 3 month |
|---|---|---|
| 2022-06-30 | 39.00 position 10-K · filed 2024-03-19 | |
| 2022-05-16 | 39.00 position 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |